Pigment Cell & Melanoma Research

Papers
(The TQCC of Pigment Cell & Melanoma Research is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Issue Information124
29
24
Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st‐line BRAF‐targeted therapy23
Molecular heterogeneity of quiescent melanocyte stem cells revealed by single‐cell RNA ‐sequencing22
TRIM 63 Promotes the Malignant Behaviors of Melanoma Cells Through Ubiquitination of P 2 RY20
CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma18
Cytoglobin functions as a redox regulator of melanogenesis in normal epidermal melanocytes17
SASH1 Mutations and Hereditary Disorders of Pigmentation: Review of Literature17
Oral Melanoma in Older Adults: Epidemiology, Molecular Landscape, and Treatment Strategies16
Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA)16
Copy Number Analysis in Congenital Nevi: Concordance and Diagnostic Limitations of aCGH , sWGS , a16
Fusion Gene Detection in Driver Mutation‐Negative Melanomas Using RNA ‐Based Anchored Multiplex Polymerase Chain Reaction16
25th International Pigment Cell Conference, Bilbao, Spain IPCC 202315
Issue Information15
Progress in melanoma treatment: Patient's perspectives15
Issue Information15
Issue Information14
Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma14
Modeling of pigmentation disorders associated with MITF mutation in Waardenburg syndrome revealed an impaired melanogenesis pathway in iPS‐derived melanocytes13
Microfluidic Characterization and Analysis of Circulating Tumor Cells From Patients With Metastatic Melanoma13
The Melanocyte and Nerve Fiber Cross‐Talk, Facilitated Also by Semaphorin‐4A, Enhances UV‐B‐Induced Melanogenesis12
Issue Information12
12
Celebrating the life of James J. Nordlund, MD, a larger‐than‐life scholar, mentor, and friend11
Sex Differences in Acral Lentiginous Melanoma: A Retrospective Cohort Analysis of 3617 Cases From the Surveillance, Epidemiology, and End Results Database11
PASPCR 2024 Annual Meeting, New York, NY11
First Report of Oculocutaneous Albinism Type I Among Baka Pygmies From Cameroon11
Issue Information11
Single‐cell profiling of MC1R‐inhibited melanocytes10
Impact of Multigene Panel Testing in High‐Risk Uveal Melanoma Patients10
MelOD : The Melanoma Omics Dashboard for Multimodal Data Exploration10
Cover Image10
Prognostic value of clinical and radiomic parameters in patients with liver metastases from uveal melanoma9
Mouse Tail‐Skin Dissociation and Preparation of Live Single‐Cell Suspension for Downstream Analysis of Melanocytes9
Rapid Diagnosis and Subtyping of Hermansky‐Pudlak Syndrome With Flow Cytometry Analysis9
BORIS / CTCFL ‐mediated chromatin accessibility alterations promote a pro‐invasive transcriptional signature in melano9
MetFinder: A Tool for Automated Quantitation of Metastatic Burden in Histological Sections From Preclinical Models9
Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 20238
Association Between Melanoma Metastasis and Metabolic Syndrome: A Cross‐Sectional Study in a Chinese Population8
8
Issue Information8
Cover Image8
Dominant Negative Mitf Allele Impacts Melanophore and Xanthophore Development and Reveals Collaborative Interactions With Tfec in Zebrafish Chromatophore Lineages8
Characterizing the Mutational Landscape of In‐Transit Melanoma Metastases8
8
CD40 Agonist Therapy in Melanoma: Translating Preclinical Promise Into Clinical Practice7
Immune signatures in cutaneous melanoma correlate with survival independently of immunotherapy treatment7
Two novel CreERT2 transgenic mouse lines to study melanocytic cells in vivo7
SASH1 Modulates Melanin Synthesis and Melanoma Cell Metastasis via Suppression of the TGF ‐β Signaling Pathway7
Histopathological Analysis Revealed Melanosome‐Retaining Fibroblasts and Autophagy‐Impaired Macrophages in Ashy Dermatosis7
Topical antibiotics limit depigmentation in a mouse model of vitiligo7
5,6‐Dihydroxyindole eumelanin content in human skin with varying degrees of constitutive pigmentation7
Beyond the 5‐year milestone: Long‐term survivorship of melanoma patients treated off‐trial with anti‐PD‐17
Rare Melanomas: An Area of Urgent Research and Clinical Need7
The metabolism of melanin synthesis—From melanocytes to melanoma7
The Proposed Categorization of Vitiligo Lesions on the Hands6
Induced pluripotent stem cells reprogramming overcomes technical limitations for highly pigmented adult melanocyte amplification and integration in 3D skin model6
Pathogenic Germline Variants in Uveal Melanoma Driver and BAP1‐Associated Genes in Finnish Patients with Uveal Melanoma6
ToFSIMS imaging reveals changes in tumor cell lipids during metastatic progression of melanoma6
Prognostic and Predictive Value of ctDNA for Metastatic Uveal Melanoma: A Systematic Review and Meta‐Analysis6
The OSUMMER lines: A series of ultraviolet‐accelerated NRAS‐mutant mouse melanoma cell lines syngeneic to C57BL/66
2‐Mercaptonicotinoyl glycine, a new potent melanogenesis inhibitor, exhibits a unique mode of action while preserving melanocyte integrity6
Connecting the dots: Melanoma cell of origin, tumor cell plasticity, trans‐differentiation, and drug resistance6
Pigmentation and Retinal Pigment Epithelium Thickness: A Study of the Phenotypic and Genotypic Relationships Between Ocular and Extraocular Pigmented Tissues6
Unsuspected consequences of synonymous and missense variants in OCA2 can be detected in blood cell RNA samples of patients with albinism6
Patient Education in the Eye of the Beholder: Assessing the Effect of Skin Color Representation in Melanoma Educational Materials6
UVA Irradiation Promotes Melanoma Cell Proliferation Mediated by OPN3 Independently of ROS Production6
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variants6
Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 20256
Genetic and phenotypic heterogeneity of multiple lentigines and precise diagnosis in four Chinese families with multiple lentigines6
Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab5
Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era5
Advancements in melanoma cancer metastasis models5
Clinicopathological features, current status, and progress of primary central nervous system melanoma diagnosis and treatment5
Segregation Between an Ornamental and a Disease Driver Gene Provides Insights Into Pigment Cell Regulation5
5
Primary cutaneous melanoma in Black patients: An analysis of 2464 cases from the National Cancer Database 2004–20185
Chemiexcitation in Ex Vivo Porcine Skin Model5
Comparison of Disease Progression Between Amelanotic Melanoma and Melanotic Melanoma5
Chicken Shank Color Determined by Inhibition of Dermal Melanin ( ID ) is Mediated by a Structural 5
Issue Information5
Cutaneous Pigment Cell Distributions and Skin Structure of Xenopus5
5
Extreme Tumor Mutational Burden Predicts Near‐Curative Outcomes With Checkpoint Immunotherapy in Melanoma: Half the Eligible, Half the Cure5
Checkpoint kinase 1 inhibitor + low‐dose hydroxyurea efficiently kills BRAF inhibitor‐ and immune checkpoint inhibitor‐resistant melanomas5
The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta‐analysis5
TFE3 promotes ferroptosis in melanoma5
5
An Evolutionary Patient Journey in Uveal Melanoma5
Myron Gordon Award Lecture 2023: Painting the neural crest: How studying pigment cells illuminates neural crest cell biology5
Neutrophil‐to‐eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti‐PD‐1 therapy5
0.085469961166382